View
Page
N1Singer put out a note this morning on it... "The merger between Skyepharma and Vectura has created a global leader in the development of therapeutic respiratory products, with strong global partners and broad development capability across multiple formulation platforms, drug classes and delivery forms. In this report we outline the company’s three strongest valuation drivers, a selection of high-potential development programmes and the financial outlook for the enlarged group." taken from Research Tree
Latest from the Community...
Latest from the Community...
Latest from the Community...
